

Special Issue

Advances in Immunotherapy for Hematological Malignancies

Message from the Guest Editors

Wish you all a very happy and productive new year 2022!

In this issue, we are inviting original articles/focused reviews reporting such advancements that change the landscape of treatment for hematological malignancies.

These articles are not limited to approaches such as chimeric antigen receptor (CAR) T-cells (CAR-T), CAR macrophages (CAR-Ma), CAR natural killer cells (CAR-NK), UltraCAR-T, and bispecific T cell engagers (BiTES) but also include drug immunoconjugate, cancer vaccine, and various combination strategies to improve the efficacy or avoid immunotherapy-based treatment resistance. Keywords

- immunotherapy
- hematological malignancies
- CAR-T
- BiTES
- CAR-NK
- CAR-Ma
- UltraCART
- DNA vaccine
- immunoconjugate
- combination therapies
- immune checkpoint blockade

Guest Editors

Dr. Anilkumar Gopalakrishnapillai

Dr. Jonathan Fisher

Dr. Raju K. Pillai

Deadline for manuscript submissions

closed (31 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/108904

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)